Edition:
United Kingdom

BioLine RX Ltd (BLRX.OQ)

BLRX.OQ on NASDAQ Stock Exchange Capital Market

1.09USD
12 Dec 2017
Change (% chg)

$-0.01 (-0.91%)
Prev Close
$1.10
Open
$1.11
Day's High
$1.11
Day's Low
$1.07
Volume
42,968
Avg. Vol
62,343
52-wk High
$1.38
52-wk Low
$0.80

Summary

Name Age Since Current Position

Aharon Schwartz

75 2003 Chairman of the Board

Philip Serlin

56 2016 Chief Executive Officer

Mali Zeevi

2016 Chief Financial Officer

Merril Gersten

2016 Chief Scientific Officer

Moshe Phillip

59 2004 Vice President of Medical Affairs and Senior Clinical Advisor

David Malek

35 2011 Vice President - Business Development

Leah Klapper

1 2010 General Manager, BioLine Innovations Jerusalem

Michael Anghel

78 2010 Director

Jacob Friedman

44 2007 Director

Raphael Hofstein

63 2003 Director

Sandra Panem

70 2014 Director

Nurit Benjamini

50 2010 External Director

Avraham Molcho

56 2010 External Director

Biographies

Name Description

Aharon Schwartz

Dr. Aharon Schwartz serves as Chairman of the Board at BioLine Rx Ltd since April 3, 2003. He has experience in ethical and generic pharmaceutical industry. He joined Teva Pharmaceuticals in 1975, and has since held various positions, including Vice President (VP), Head of the Commercial Division, Vice President Head of Teva-Israel and Vice President Business Development. While acting as VP Global Products, Dr. Schwartz was responsible for bringing Teva's first ethical drug to market through strategic cooperation with international pharmaceutical companies. Dr. Schwartz also served as Chairman of Denx and Immudar and is a Director at Transpharma; Curetech; Proteologics, Meytav, BioLine Innovations Jerusalem Ltd, Clal Biotechnology Ltd. He is Non-Executive Member of the Board of Directors of Clal Biotechnology Industries Ltd., Proteologic Ltd, and Mediwound Ltd. Dr. Schwartz holds a Bachelor of Science degree in Chemistry and Physics from The Hebrew University of Jerusalem, a Master of Science degree in Chemistry from The Technion-Israel Institute of Technology and a Doctorate in Philosophy degree in Organic Chemistry from The Weizmann Institute of Science.

Philip Serlin

Mr. Philip (Phil) A. Serlin has been appointed Chief Executive Officer at BioLine Rx Ltd effective October 10, 2016. Until this date, he will continue to serve as Chief Financial Officer and Chief Operating Officer at the Company, as he has since May, 2009. Prior to joining BioLineRx, Mr. Serlin was Chief Financial Officer and Chief Operating Officer of Kayote Networks Ltd. Mr. Serlin also served as Chief Financial Officer of Tescom Software Systems Testing Ltd. His background also includes senior positions at Chiaro Networks Ltd. and at Deloitte, where he was head of the SEC and U.S. accounting department at the National Office in Tel Aviv, as well as seven years at the SEC at its Washington, D.C., headquarters. Mr. Serlin is a Certified Public Accountant and holds a Masters degree in Economics and Public Policy from The George Washington University and a Bachelors degree in Accounting from Yeshiva University.

Mali Zeevi

Ms. Mali Zeevi has been appointed Chief Financial Officer at BioLine Rx Ltd effective October 10, 2016. Until this date, she will continue to serve as Finance Director at the Company, as she has since 2009. Before joining BioLineRx, Ms. Zeevi was employed by Tescom Software Systems Testing Ltd., her last position there being Vice President Finance. Ms. Zeevi also served as a CPA at Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited. She holds a Bachelors degree in Accounting and Business Management from Hamichlala Leminhal. She is a Certified Public Accountant.

Merril Gersten

Moshe Phillip

Prof. Moshe Phillip serves as Vice President of Medical Affairs and Senior Clinical Advisor for BioLine Rx Ltd since 2004. He is Director of the Institute for Endocrinology and Diabetes, Israel National Center for Childhood Diabetes and served as the Vice Dean and Head of School for Continuing Medical Education of the Sackler School of Medical Education at Tel Aviv University. He manages the Institute's Clinical Research Center, with in-house research coordinators, statisticians, nurses and physicians. Prof. Phillip is the senior PI of numerous clinical studies including Growth Hormone (norditropin), Lantus (Sanofi Aventis), Detemir (Novo Nordisk), Candersartan Cilexetil (Astra Zeneca), and Medtronic's patented insulin pump and glucose sensors. Prof. Phillip's experience in both bench and clinical research includes clinical studies from Phase II to post marketing. His bench research is focused mainly on finding ways to prevent diabetic complications and understanding the interaction between hormones and the epiphyseal growth plate, while his clinical research focuses on diabetes and growth, including studies in immunomodulation and prevention of diabetes mellitus. Prof. Phillip is an Associate Editor and on the editorial board of three medical journals and a member of the Pediatric and Diabetic National Councils of Health. He holds a Doctorate of Medicine degree from the Ben Gurion University of the Negev and a fellowship in pediatric endocrinology at the University Of Maryland School Of Medicine.

David Malek

Leah Klapper

Michael Anghel

Dr. Michael J. Anghel serves as Director at BioLine Rx Ltd since September 7, 2010. He also serves as Member of the Boards of Directors of Orbotech Ltd, the Strauss-Group Ltd., Partner, Syneron Medical Ltd. From 2004, to 2005, he served as President and Chief Executive Officer of Discount Capital Markets Ltd., which is the investment banking arm of Israel Discount Bank Ltd. (IDB). In 1999, he founded CAP Ventures Ltd., an Israeli company operating and investing in the area of Israeli advanced technology ventures, and served as its Managing Director from 1999, to 2004. From 1977, to May 1999, he served as Director and Senior Manager of Discount Investment Corporation Ltd. (DIC), an Israeli corporation, and as Managing Director of DIC Communication and Technology Ltd., a wholly owned subsidiary of DIC. In addition, during this period he served on the Boards of Directors of a number of Israeli Nasdaq-listed companies connected with DIC and PEC Israel Economic Corporation, a Maine corporation, including Elron Electronic Industries Ltd. (Elron), Elscint Ltd., Elbit Medical Imaging Ltd., Nice Systems Ltd. (Nice) and Gilat Satellite Networks Ltd. Dr. Anghel has been instrumental in founding several Israeli communications operating companies including the principal Israeli cable television company (Tevel Israel International Communications Ltd.) and the Israeli cellular telephone company Cellcom Israel Ltd., as well as a variety of other advanced technology ventures. Dr. Anghel was formerly a full-time member of the faculty of the Graduate School of Business Administration of Tel Aviv University and currently serves as Chairman of its Executive Program. In 1969, he received his PhD in Internal Finance and in 1964, an MBA degree in Finance and Economics, both from Columbia University and in 1960 he received his MBA in Economics from The Hebrew University of Jerusalem.

Jacob Friedman

Mr. Jacob Friedman serves as Director at BioLine Rx Ltd since February 8, 2007. Mr. Friedman has worked as an Analyst for Friedberg Mercantile Group Ltd since 2001. Mr. Friedman holds a BSC degree in Management, an MBA degree in management and a LLM degree, all from the York University.

Raphael Hofstein

Dr. Raphael Hofstein serves as Director at BioLine Rx Ltd since April 3, 2003. He has experience in life-sciences development and management. He was President and Chief Executive Officer of Hadasit Ltd., the Technology Holdings Company of Hadassah Medical Organization between 2000 and 2009. Prior to that, Dr. Hofstein served as the President of Mindsense Biosystems Ltd. where he was responsible for the business development and overall company communications with the investment community as well as budget planning. He also served as Business Unit Director of Ecogen Inc. in Langhorne PA after serving as the Scientific Director of its Israel office. Dr. Hofstein serves on the board of directors of numerous companies, including Hadasit Bio-Holdings Ltd. Dr. Hofstein holds a Bachelor of Science in Chemistry and Physics from The Hebrew University of Jerusalem from 1974, a Master of Science degree in Biochemistry since 1975, and a Doctorate in Philosophy degree in Life Sciences, both from The Weizmann Institute of Science in 1980. He completed postdoctoral training at the Harvard Medical School in Boston, in both the departments of biological chemistry and neurobiology.

Sandra Panem

Dr. Sandra Panem, Ph.D. is Director of the Company. Dr. Panem has had an extensive and impressive career in the healthcare and life sciences industries in the U.S. Her experience encompasses corporate and financial strategy, corporate governance, venture capital, technology assessment, research management and public policy. Dr. Panem is currently a Managing Partner at Cross Atlantic Partners and serves on the Board of Directors of Acorda Therapeutics, Inc. (NASDAQ: ACOR), GenomeQuest, Inc., Labcyte, Inc. and MDx Medical (Vitals.com). Dr. Panem has served on numerous Boards of public and private companies, including Martek Biosciences (NASDAQ:MATK), IBAH Pharmaceuticals (IBAH), Confluent Surgical and Molecular Informatics. Her previous positions include President of Vector Fund Management; Vice President and Portfolio Manager for the Oppenheimer Global BioTech Fund, a mutual fund that invested in public and private biotechnology companies; and Vice President at Salomon Brothers Venture Capital, a fund focused on early and later-stage life sciences and technology investments. She was also a Science and Public Policy Fellow in economic studies at the Brookings Institution, and an Assistant Professor of Pathology at the University of Chicago. Dr. Panem received a B.Sc. in Biochemistry and a Ph.D. in Microbiology from the University of Chicago.

Nurit Benjamini

Ms. Nurit Benjamini serves as External Director at BioLine Rx Ltd since July 6, 2010. Previously, she served as Chief Financial Officer at Compugen Ltd. Prior to this, Ms. Benjamini served as CFO at Phone-Or Ltd. Between 1993 and 1998, and as CFO at Aladdin Knowledge Systems Ltd. Ms. Benjamini holds a Bachelor of Arts degree in Business and Economics and a Master of Business Administration degree in Finance, both from Bar-Ilan University.

Avraham Molcho

Dr. Avraham Molcho serves as External Director at BioLine Rx Ltd since July 6, 2010. He also serves as Director at D-Pharm Ltd. Circulite Inc., Pathway Medical Inc. He is Founder and Chairman of Biological Design, partner at Forbion Capital Partners. Previously, Dr. Molcho served as Chief Executive Officer (CEO) and Chairman at Neovasc Medical and as Managing Director, Head of Life Sciences at Giza Venture Capital. He was Deputy Director General at Abarbanel Mental Health Center and has held a number of other medical positions. Dr. Molcho holds a Master of Business Administration degree and Doctorate of Medicine degree, both from the Tel-Aviv University. He carried out postdoctoral training at the Albert Einstein College of Medicine, N.Y in the department of psychopharmacology and Columbia University College of Physicians and Surgeons at the Division of Neuroscience.